Heteroaromatic PI3K Inhibitors for Selective Kinase Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors for phosphatidylinositol 3-kinases (PI3K) and mammalian target of rapamycin (mTOR) have limitations in effectively targeting and modulating these key kinases, particularly in cancer treatment, where PI3K signaling pathways are frequently dysregulated.
Innovation Solution
Development of specific compounds, such as those represented by Formula (I), which inhibit, regulate, or modulate PI3K and/or mTOR, are designed to treat hyperproliferative diseases like cancer by administering these compounds or their pharmaceutical compositions, either alone or in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current inhibitors are used to target PI3K and mTOR, then some level of kinase inhibition is achieved, but the effectiveness and selectivity in modulating these key kinases is insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures of PI3K inhibitors to achieve optimal binding affinity and selectivity. Specific substitutions at defined positions in the molecular scaffold (Formula I) alter pharmacological properties, enabling effective modulation of PI3K and mTOR kinases while maintaining manageable synthesis complexity
Solution Approach 2:
The invention employs composite molecular structures combining multiple functional groups and heteroaromatic moieties in a unified scaffold (Formula I). This composite approach creates inhibitors with enhanced potency and selectivity for PI3K/mTOR, resolving the contradiction between effectiveness and design complexity by integrating multiple pharmacophoric elements into a single optimized molecule
2Adaptability or versatility
If broad-spectrum kinase inhibitors are used, then multiple kinase targets are covered, but specificity for PI3K and mTOR is reduced
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and heteroaromatic substitutions at defined positions in the molecular scaffold (Formula I). These localized structural features create precise interactions with PI3K and mTOR binding pockets, enhancing specificity while maintaining the ability to inhibit multiple kinases within the PI3K family through conserved binding regions
Data Source
AI summary
The present invention provides heteroaromatic derivatives of formula (I) and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.